MAPT and Alzheimer disease: A study in vivo used nSMase2- deficient 5XFAD mice with reduced ceramide generation to assess AD-related pathology and demonstrated the release of astrocyte-derived EVs containing tau phosphorylation and Aβ42 plaque burden was increased in the AD mouse model (Dinkins et al., 2016).